Searching Genes Encoding <i>Leishmania</i> Antigens for Diagnosis and Protection

Soto, Manuel; Ramírez, Laura; Pineda, Miguel A.; González, Victor M.; Entringer, Petter F.; de Oliveira, Camila Indiani; Nascimento, Ivan P.; Souza, Ana P.; Corvo, Laura; Alonso, Carlos; Bonay, Pedro; Brodskyn, Claudia; Barral, Aldina; Barral-Netto, Manoel; Iborra, Salvador

doi:https://doi.org/10.3814/2009/173039

Scholarly Research Exchange

On this page

Abstract References Copyright Related Articles

Review Article | Open Access

Volume 2009 | Article ID 173039 | https://doi.org/10.3814/2009/173039

Searching Genes Encoding Leishmania Antigens for Diagnosis and Protection

Manuel Soto,¹Laura Ramírez,¹Miguel A. Pineda,¹Victor M. González,²Petter F. Entringer,³Camila Indiani de Oliveira,³Ivan P. Nascimento,³Ana P. Souza,³Laura Corvo,¹Carlos Alonso,¹Pedro Bonay,¹and Claudia Brodskyn³ et al.

Received12 Jan 2009

Revised17 Apr 2009

Accepted14 May 2009

Published11 Jun 2009

Abstract

Leishmaniases are a wide spectrum of parasitic diseases caused by the infection of different species of the genus Leishmania. Currently, these diseases are one of the most neglected diseases threatening 350 million people in different countries around the world. Thus, these diseases require better screening, diagnostics and treatment. An effective vaccine, that is not currently available, would be the best way to confront leishmaniases. In the past 20 years the molecular characterization of Leishmania genes encoding parasite antigens has been carried out. In this review we summarize the most common strategies employed for the isolation and characterization of genes encoding Leishmania antigens. To provide a collective view, we also discuss the results related with diagnosis and protection based on different recombinant DNA-derived Leishmania products.

References

B. L. Herwaldt, “Leishmaniasis,” The Lancet, vol. 354, no. 9185, pp. 1191–1199, 1999.
View at: Publisher Site | Google Scholar
M. Gramiccia and L. Gradoni, “The current status of zoonotic leishmaniases and approaches to disease control,” International Journal for Parasitology, vol. 35, no. 11-12, pp. 1169–1180, 2005.
View at: Publisher Site | Google Scholar
G. M. Santos-Gomes, R. Rosa, C. Leandro, S. Cortes, P. Romão, and H. Silveira, “Cytokine expression during the outcome of canine experimental infection by Leishmania infantum,” Veterinary Immunology and Immunopathology, vol. 88, no. 1-2, pp. 21–30, 2002.
View at: Publisher Site | Google Scholar
L. Gradoni, “An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine,” Veterinary Parasitology, vol. 100, no. 1-2, pp. 87–103, 2001.
View at: Publisher Site | Google Scholar
D. McMahon-Pratt and J. Alexander, “Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?,” Immunological Reviews, vol. 201, no. 1, pp. 206–224, 2004.
View at: Publisher Site | Google Scholar
H. D. F. H. Schallig and L. Oskam, “Molecular biological applications in the diagnosis and control of leishmaniasis and parasite identification,” Tropical Medicine and International Health, vol. 7, no. 8, pp. 641–651, 2002.
View at: Publisher Site | Google Scholar
K. Kar, “Serodiagnosis of leishmaniasis,” Critical Reviews in Microbiology, vol. 21, no. 2, pp. 123–152, 1995.
View at: Publisher Site | Google Scholar
J. Kubar and K. Fragaki, “Recombinant DNA-derived Leishmania proteins: from the laboratory to the field,” The Lancet Infectious Diseases, vol. 5, no. 2, pp. 107–114, 2005.
View at: Publisher Site | Google Scholar
R. N. Coler and S. G. Reed, “Second-generation vaccines against leishmaniasis,” Trends in Parasitology, vol. 21, no. 5, pp. 244–249, 2005.
View at: Publisher Site | Google Scholar
E. Handman, “Leishmaniasis: current status of vaccine development,” Clinical Microbiology Reviews, vol. 14, no. 2, pp. 229–243, 2001.
View at: Publisher Site | Google Scholar
F. Modabber, “Vaccines against leishmaniasis,” Annals of Tropical Medicine and Parasitology, vol. 89, pp. 83–88, 1995.
View at: Google Scholar
C. L. Greenblatt, “The present and future of vaccination for cutaneous leishmaniasis,” Progress in Clinical and Biological Research, vol. 47, pp. 259–285, 1980.
View at: Google Scholar
O. I. Kellina, “Problem and current lines in investigations on the epidemiology of leishmaniasis and its control in the U.S.S.R,” Bulletin de la Societe de Pathologie Exotique et de ses Filiales, vol. 74, no. 3, pp. 306–318, 1981.
View at: Google Scholar
C. B. Palatnik, R. Borojevic, J. O. Previato, and L. Mendonça-Previato, “Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate ligands,” Infection and Immunity, vol. 57, no. 3, pp. 754–763, 1989.
View at: Google Scholar
C. B. Palatnik-de-Sousa, E. M. Gomes, E. Paraguai-de-Souza, M. Palatnik, K. Luz, and R. Borojevic, “Leishmania donovani: titration of antibodies to the fucose-mannose ligand as an aid in diagnosis and prognosis of visceral leishmaniasis,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 89, no. 4, pp. 390–393, 1995.
View at: Publisher Site | Google Scholar
G. P. Borja-Cabrera, V. O. Da Silva, R. T. Da Costa et al., “The fucose-mannose ligand-ELISA in the diagnosis and prognosis of canine visceral leishmaniasis in Brazil,” The American Journal of Tropical Medicine and Hygiene, vol. 61, no. 2, pp. 296–301, 1999.
View at: Google Scholar
L. E. Parra, G. P. Borja-Cabrera, F. N. Santos, L. O. P. Souza, C. B. Palatnik-de-Sousa, and I. Menz, “Safety trial using the Leishmune $^{®}$ vaccine against canine visceral leishmaniasis in Brazil,” Vaccine, vol. 25, no. 12, pp. 2180–2186, 2007.
View at: Publisher Site | Google Scholar
C. B. Palatnik-de-Sousa, H. S. Dutra, and R. Borojevic, “Leishmania donovani surface glycoconjugate GP36 is the major immunogen component of the Fucose-Mannose Ligand (FML),” Acta Tropica, vol. 53, no. 1, pp. 59–72, 1993.
View at: Publisher Site | Google Scholar
J.-L. Lemesre, P. Holzmuller, M. Cavaleyra, R. B. Gonçalves, G. Hottin, and G. Papierok, “Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes,” Vaccine, vol. 23, no. 22, pp. 2825–2840, 2005.
View at: Publisher Site | Google Scholar
J.-L. Lemesre, P. Holzmuller, R. B. Gonçalves et al., “Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial,” Vaccine, vol. 25, no. 21, pp. 4223–4234, 2007.
View at: Publisher Site | Google Scholar
R. Rosa, O. R. Rodrigues, C. Marques, and G. M. Santos-Gomes, “Leishmania infantum: soluble proteins released by the parasite exert differential effects on host immune response,” Experimental Parasitology, vol. 109, no. 2, pp. 106–114, 2005.
View at: Publisher Site | Google Scholar
R. Rosa, C. Marques, O. R. Rodrigues, and G. M. Santos-Gomes, “Immunization with Leishmania infantum released proteins confers partial protection against parasite infection with a predominant Th1 specific immune response,” Vaccine, vol. 25, no. 23, pp. 4525–4532, 2007.
View at: Publisher Site | Google Scholar
L. L. Button and W. R. McMaster, “Molecular cloning of the major surface antigen of Leishmania,” Journal of Experimental Medicine, vol. 167, no. 2, pp. 724–729, 1988.
View at: Publisher Site | Google Scholar
K. L. Lohman, P. J. Langer, and D. McMahon-Pratt, “Molecular cloning and characterization of the immunologically protective surface glycoprotein GP46/M-2 of Leishmania amazonensis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 21, pp. 8393–8397, 1990.
View at: Publisher Site | Google Scholar
A. Jardim, S. Hanson, B. Ullman, W. D. McCubbin, C. M. Kay, and R. W. Olafson, “Cloning and structure-function analysis of the Leishmania donovani kinetoplastid membrane protein-11,” Biochemical Journal, vol. 305, part 1, pp. 315–320, 1995.
View at: Google Scholar
C. E. Clayton, “Life without transcriptional control? From fly to man and back again,” The EMBO Journal, vol. 21, no. 8, pp. 1881–1888, 2002.
View at: Publisher Site | Google Scholar
J. E. Donelson, M. J. Gardner, and N. M. El-Sayed, “More surprises from Kinetoplastida,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 6, pp. 2579–2581, 1999.
View at: Publisher Site | Google Scholar
J. R. Webb, A. Campos-Neto, P. J. Ovendale et al., “Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family,” Infection and Immunity, vol. 66, no. 7, pp. 3279–3289, 1998.
View at: Google Scholar
B. Yahiaoui, M. Loyens, A. Taibi, R. Schöneck, J. F. Dubremetz, and M. A. Ouaissi, “Characterization of a Leishmania antigen associated with cytoplasmic vesicles resembling endosomal-like structure,” Parasitology, vol. 107, part 5, pp. 497–507, 1993.
View at: Google Scholar
P. J. Murray, T. W. Spithill, and E. Handman, “The PSA-2 glycoprotein complex of Leishmania major is a glycosylphosphatidylinositol-linked promastigote surface antigen,” The Journal of Immunology, vol. 143, no. 12, pp. 4221–4226, 1989.
View at: Google Scholar
L. Quijada, J. M. Requena, M. Soto et al., “Mapping of the linear antigenic determinants of the Leishmania infantum Hsp70 recognized by leishmaniasis sera,” Immunology Letters, vol. 52, no. 2-3, pp. 73–79, 1996.
View at: Publisher Site | Google Scholar
M. Soto, J. M. Requena, and C. Alonso, “Isolation, characterization and analysis of the expression of the Leishmania ribosomal PO protein genes,” Molecular and Biochemical Parasitology, vol. 61, no. 2, pp. 265–274, 1993.
View at: Publisher Site | Google Scholar
M. Soto, J. M. Requena, M. Garcia, L. C. Gomez, I. Navarrete, and C. Alonso, “Genomic organization and expression of two independent gene arrays coding for two antigenic acidic ribosomal proteins of Leishmania,” The Journal of Biological Chemistry, vol. 268, no. 29, pp. 21835–21843, 1993.
View at: Google Scholar
M. Soto, J. M. Requena, L. C. Gomez, I. Navarrete, and C. Alonso, “Molecular characterization of a Leishmania donovani infantum antigen identified as histone H2A,” European Journal of Biochemistry, vol. 205, no. 1, pp. 211–216, 1992.
View at: Publisher Site | Google Scholar
M. Soto, J. M. Requena, G. Morales, and C. Alonso, “The Leishmania infantum histone H3 possesses an extremely divergent N-terminal domain,” Biochimica et Biophysica Acta, vol. 1219, no. 2, pp. 533–535, 1994.
View at: Publisher Site | Google Scholar
S. O. Angel, J. M. Requena, M. Soto, D. Criado, and C. Alonso, “During canine leishmaniasis a protein belonging to the 83-kDa heat-shock protein family elicits a strong humoral response,” Acta Tropica, vol. 62, no. 1, pp. 45–56, 1996.
View at: Publisher Site | Google Scholar
J. MacFarlane, M. L. Blaxter, R. P. Bishop, M. A. Miles, and J. M. Kelly, “Identification and characterisation of a Leishmania donovani antigen belonging to the 70-kDa heat-shock protein family,” European Journal of Biochemistry, vol. 190, no. 2, pp. 377–384, 1990.
View at: Publisher Site | Google Scholar
J. M. Burns, Jr., J. M. Scott, E. M. Carvalho et al., “Characterization of a membrane antigen of Leishmania amazonensis that stimulates human immune responses,” The Journal of Immunology, vol. 146, no. 2, pp. 742–748, 1991.
View at: Google Scholar
Y. A. Skeiky, J. A. Guderian, D. R. Benson et al., “A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12,” Journal of Experimental Medicine, vol. 181, no. 4, pp. 1527–1537, 1995.
View at: Publisher Site | Google Scholar
Y. A. Skeiky, D. R. Benson, J. A. Guderian et al., “Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans,” Infection and Immunity, vol. 63, no. 10, pp. 4105–4114, 1995.
View at: Google Scholar
J. R. Webb, D. Kaufmann, A. Campos-Neto, and S. G. Reed, “Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis,” The Journal of Immunology, vol. 157, no. 11, pp. 5034–5041, 1996.
View at: Google Scholar
N. Santarém, R. Silvestre, J. Tavares et al., “Immune response regulation by Leishmania secreted and nonsecreted antigens,” Journal of Biomedicine and Biotechnology, vol. 2007, Article ID 85154, 10 pages, 2007.
View at: Publisher Site | Google Scholar
J. M. Requena, C. Alonso, and M. Soto, “Evolutionarily conserved proteins as prominent immunogens during Leishmania infections,” Parasitology Today, vol. 16, no. 6, pp. 246–250, 2000.
View at: Publisher Site | Google Scholar
F. Y. Liew and C. A. O'Donnell, “Immunology of Leishmaniasis,” Advances in Parasitology, vol. 32, pp. 161–259, 1993.
View at: Publisher Site | Google Scholar
J. M. Requena, S. Iborra, J. Carrión, C. Alonso, and M. Soto, “Recent advances in vaccines for leishmaniasis,” Expert Opinion on Biological Therapy, vol. 4, no. 9, pp. 1505–1517, 2004.
View at: Publisher Site | Google Scholar
R. M. Locksley and J. A. Louis, “Immunology of leishmaniasis,” Current Opinion in Immunology, vol. 4, no. 4, pp. 413–418, 1992.
View at: Publisher Site | Google Scholar
P. Scott, P. Caspar, and A. Sher, “Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes,” The Journal of Immunology, vol. 144, no. 3, pp. 1075–1079, 1990.
View at: Google Scholar
E. Mougneau, F. Altare, A. E. Wakil et al., “Expression cloning of a protective Leishmania antigen,” Science, vol. 268, no. 5210, pp. 563–566, 1995.
View at: Publisher Site | Google Scholar
P. Probst, E. Stromberg, H. W. Ghalib et al., “Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning,” The Journal of Immunology, vol. 166, no. 1, pp. 498–505, 2001.
View at: Google Scholar
S. Gurunathan, D. M. Klinman, and R. A. Seder, “DNA vaccines: immunology, application, and ${optimization}^{*}$ ,” Annual Review of Immunology, vol. 18, pp. 927–974, 2000.
View at: Publisher Site | Google Scholar
P. M. Smooker, A. Rainczuk, N. Kennedy, and T. W. Spithill, “DNA vaccines and their application against parasites—promise, limitations and potential solutions,” Biotechnology Annual Review, vol. 10, pp. 189–236, 2004.
View at: Publisher Site | Google Scholar
D. Piedrafita, D. Xu, D. Hunter, R. A. Harrison, and F. Y. Liew, “Protective immune responses induced by vaccination with an expression genomic library of Leishmania major,” The Journal of Immunology, vol. 163, no. 3, pp. 1467–1472, 1999.
View at: Google Scholar
P. C. Melby, G. B. Ogden, H. A. Flores et al., “Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library,” Infection and Immunity, vol. 68, no. 10, pp. 5595–5602, 2000.
View at: Publisher Site | Google Scholar
C. B. Stober, U. G. Lange, M. T. M. Roberts et al., “From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection,” Vaccine, vol. 24, no. 14, pp. 2602–2616, 2006.
View at: Publisher Site | Google Scholar
N. J. Fasel, D. C. Robyr, J. Mauel, and T. A. Glaser, “Identification of a histone H1-like gene expressed in Leishmania major,” Molecular and Biochemical Parasitology, vol. 62, no. 2, pp. 321–324, 1993.
View at: Publisher Site | Google Scholar
R. M. R. Coulson and D. F. Smith, “Isolation of genes showing increased or unique expression in the infective promastigotes of Leishmania major,” Molecular and Biochemical Parasitology, vol. 40, no. 1, pp. 63–75, 1990.
View at: Publisher Site | Google Scholar
H. Charest and G. Matlashewski, “Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigote-stage-specific gene,” Molecular and Cellular Biology, vol. 14, no. 5, pp. 2975–2984, 1994.
View at: Google Scholar
B. Yahiaoui, A. Taibi, and A. Ouaissi, “A Leishmania major protein with extensive homology to silent information regulator 2 of Saccharomyces cerevisiae,” Gene, vol. 169, no. 1, pp. 115–118, 1996.
View at: Publisher Site | Google Scholar
Y. Goto, R. F. Howard, A. Bhatia et al., “Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs,” Veterinary Parasitology, vol. 160, no. 3-4, pp. 215–220, 2009.
View at: Publisher Site | Google Scholar
R. A. Frye, “Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins,” Biochemical and Biophysical Research Communications, vol. 273, no. 2, pp. 793–798, 2000.
View at: Publisher Site | Google Scholar
S. M. Gasser and M. M. Cockell, “The molecular biology of the SIR proteins,” Gene, vol. 279, no. 1, pp. 1–16, 2001.
View at: Publisher Site | Google Scholar
B. Vergnes, D. Sereno, N. Madjidian-Sereno, J.-L. Lemesre, and A. Ouaissi, “Cytoplasmic SIR2 homologue overexpression promotes survival of Leishmania parasites by preventing programmed cell death,” Gene, vol. 296, no. 1-2, pp. 139–150, 2002.
View at: Publisher Site | Google Scholar
K. Zemzoumi, D. Sereno, C. François, E. Guilvard, J.-L. Lemesre, and A. Ouaissi, “Leishmania major: cell type dependent distribution of a 43 kDa antigen related to silent information regulatory-2 protein family,” Biology of the Cell, vol. 90, no. 3, pp. 239–245, 1998.
View at: Publisher Site | Google Scholar
R. Silvestre, A. Cordeiro-da-Silva, J. Tavares, D. Sereno, and A. Ouaissi, “Leishmania cytosolic silent information regulatory protein 2 deacetylase induces murine B-cell differentiation and in vivo production of specific antibodies,” Immunology, vol. 119, no. 4, pp. 529–540, 2006.
View at: Publisher Site | Google Scholar
A. Cordeiro-da-Silva, L. Cardoso, N. Araújo et al., “Identification of antibodies to Leishmania silent information regulatory 2 (SIR2) protein homologue during canine natural infections: pathological implications,” Immunology Letters, vol. 86, no. 2, pp. 155–162, 2003.
View at: Publisher Site | Google Scholar
N. Santarém, A. Tomás, A. Ouaissi et al., “Antibodies against a Leishmania infantum peroxiredoxin as a possible marker for diagnosis of visceral leishmaniasis and for monitoring the efficacy of treatment,” Immunology Letters, vol. 101, no. 1, pp. 18–23, 2005.
View at: Publisher Site | Google Scholar
P. F. P. Pimenta, E. M. B. Saraiva, and D. L. Sacks, “The comparative fine structure and surface glycoconjugate expression of three life stages of Leishmania major,” Experimental Parasitology, vol. 72, no. 2, pp. 191–204, 1991.
View at: Publisher Site | Google Scholar
M. A. J. Ferguson, “The surface glycoconjugates of trypanosomatid parasites,” Philosophical Transactions of the Royal Society B, vol. 352, no. 1359, pp. 1295–1302, 1997.
View at: Publisher Site | Google Scholar
M. J. McConville and J. M. Blackwell, “Developmental changes in the glycosylated phosphatidylinositols of Leishmania donovani. Characterization of the promastigote and amastigote glycolipids,” The Journal of Biological Chemistry, vol. 266, no. 23, pp. 15170–15179, 1991.
View at: Google Scholar
J. Bouvier, R. J. Etges, and C. Bordier, “Identification and purification of membrane and soluble forms of the major surface protein of Leishmania promastigotes,” The Journal of Biological Chemistry, vol. 260, no. 29, pp. 15504–15509, 1985.
View at: Google Scholar
C. Yao, J. E. Donelson, and M. E. Wilson, “The major surface protease (MSP or GP63) of Leishmania sp. Biosynthesis, regulation of expression, and function,” Molecular and Biochemical Parasitology, vol. 132, no. 1, pp. 1–16, 2003.
View at: Publisher Site | Google Scholar
R. Etges, J. Bouvier, and C. Bordier, “The major surface protein of Leishmania promastigotes is a protease,” The Journal of Biological Chemistry, vol. 261, no. 20, pp. 9098–9101, 1986.
View at: Google Scholar
C. Bordier, “The promastigote surface protease of Leishmania,” Parasitology Today, vol. 3, no. 5, pp. 151–153, 1987.
View at: Publisher Site | Google Scholar
J. Bouvier, R. Etges, and C. Bordier, “Identification of the promastigote surface protease in seven species of Leishmania,” Molecular and Biochemical Parasitology, vol. 24, no. 1, pp. 73–79, 1987.
View at: Publisher Site | Google Scholar
E. A. Okong'o-Odera, J. A. L. Kurtzhals, A. S. Hey, and A. Kharazmi, “Measurement of serum antibodies against native Leishmania gp63 distinguishes between ongoing and previous L. donovani infection,” APMIS, vol. 101, no. 8, pp. 642–646, 1993.
View at: Google Scholar
W. G. Shreffler, J. M. Burns, Jr., R. Badaró et al., “Antibody responses of visceral leishmaniasis patients to gp63, a major surface glycoprotein of Leishmania species,” Journal of Infectious Diseases, vol. 167, no. 2, pp. 426–430, 1993.
View at: Google Scholar
G. Morales, G. Carrillo, J. M. Requena et al., “Mapping of the antigenic determinants of the Leishmania infantum gp63 protein recognized by antibodies elicited during canine visceral leishmaniasis,” Parasitology, vol. 114, part 6, pp. 507–516, 1997.
View at: Google Scholar
T. Sanyal, D. K. Ghosh, and D. Sarkar, “Immunoblotting identifies an antigen recognized by anti gp63 in the immune complexes of Indian kala-azar patient sera,” Molecular and Cellular Biochemistry, vol. 130, no. 1, pp. 11–17, 1994.
View at: Publisher Site | Google Scholar
T. Chakraborti, D. Sarkar, and D. K. Ghosh, “Immune complex antigens as a tool in serodiagnosis of kala-azar,” Molecular and Cellular Biochemistry, vol. 253, no. 1-2, pp. 191–198, 2003.
View at: Publisher Site | Google Scholar
E. W. Mohareb, H. A. Hanafi, E. M. Mikhail, S. M. Presley, and R. Batchelor, “Evaluation of an indirect immunofluorescence assay for the detection of Leishmania promastigotes and amastigotes in sand flies and lesion fluid aspirates,” Journal of the Egyptian Society of Parasitology, vol. 28, no. 2, pp. 313–321, 1998.
View at: Google Scholar
L. P. Kahl, R. Lelchuk, C. A. Scott, and J. Beesley, “Characterization of Leishmania major antigen-liposomes that protect BALB/c mice against cutaneous leishmaniasis,” Infection and Immunity, vol. 58, no. 10, pp. 3233–3241, 1990.
View at: Google Scholar
D. G. Russell and J. Alexander, “Effective immunization cutaneous leishmaniasis with defined membrane antigens reconsituted into liposomes,” The Journal of Immunology, vol. 140, no. 4, pp. 1274–1279, 1988.
View at: Google Scholar
F. Afrin, R. Rajesh, K. Anam, M. Gopinath, S. Pal, and N. Ali, “Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice,” Infection and Immunity, vol. 70, no. 12, pp. 6697–6706, 2002.
View at: Publisher Site | Google Scholar
S. Bhowmick, R. Ravindran, and N. Ali, “gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani,” Infection and Immunity, vol. 76, no. 3, pp. 1003–1015, 2008.
View at: Publisher Site | Google Scholar
M. R. Jaafari, A. Ghafarian, A. Farrokh-Gisour et al., “Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice,” Vaccine, vol. 24, no. 29-30, pp. 5708–5717, 2006.
View at: Publisher Site | Google Scholar
M. R. Jaafari, A. Badiee, A. Khamesipour et al., “The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome,” Vaccine, vol. 25, no. 32, pp. 6107–6117, 2007.
View at: Publisher Site | Google Scholar
D. M. Yang, N. Fairweather, L. L. Button, W. R. McMaster, L. P. Kahl, and F. Y. Liew, “Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis,” The Journal of Immunology, vol. 145, no. 7, pp. 2281–2285, 1990.
View at: Google Scholar
S. Abdelhak, H. Louzir, J. Timm et al., “Recombinant BCG expressing the Leishmania surface antigen gp63 induces protective immunity against Leishmania major infection in BALB/c mice,” Microbiology, vol. 141, part 7, pp. 1585–1592, 1995.
View at: Google Scholar
N. D. Connell, E. Medina-Acosta, W. R. McMaster, B. R. Bloom, and D. G. Russell, “Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 24, pp. 11473–11477, 1993.
View at: Publisher Site | Google Scholar
C. W. Xu, J. C. Hines, M. L. Engel, D. G. Russell, and D. S. Ray, “Nucleus-encoded histone H1-like proteins are associated with kinetoplast DNA in the trypanosomatid Crithidia fasciculata,” Molecular and Cellular Biology, vol. 16, no. 2, pp. 564–576, 1996.
View at: Google Scholar
S. Frankenburg, O. Axelrod, S. Kutner et al., “Effective immunization of mice against cutaneous leishmaniasis using an intrinsically adjuvanted synthetic lipopeptide vaccine,” Vaccine, vol. 14, no. 9, pp. 923–929, 1996.
View at: Publisher Site | Google Scholar
P. Tsagozis, E. Karagouni, and E. Dotsika, “Dendritic cells pulsed with peptides of gp63 induce differential protection against experimental cutaneous leishmaniasis,” International Journal of Immunopathology and Pharmacology, vol. 17, no. 3, pp. 343–352, 2004.
View at: Google Scholar
D. McMahon-Pratt, Y. Traub-Cseko, K. L. Lohman, D. D. Rogers, and S. M. Beverley, “Loss of the GP46/M-2 surface membrane glycoprotein gene family in the Leishmania braziliensis complex,” Molecular and Biochemical Parasitology, vol. 50, no. 1, pp. 151–160, 1992.
View at: Publisher Site | Google Scholar
L. P. Kahl and D. McMahon-Pratt, “Structural and antigenic characterization of a species- and promastigote-specific Leishmania mexicana amazonensis membrane protein,” The Journal of Immunology, vol. 138, no. 5, pp. 1587–1595, 1987.
View at: Google Scholar
I. A. Maalej, M. Chenik, H. Louzir et al., “Comparative evaluation of ELISAs based on ten recombinant or purified Leishmania antigens for the serodiagnosis of Mediterranean visceral leishmaniasis,” The American Journal of Tropical Medicine and Hygiene, vol. 68, no. 3, pp. 312–320, 2003.
View at: Google Scholar
C. Boceta, C. Alonso, and A. Jiménez-Ruiz, “Leucine rich repeats are the main epitopes in Leishmania infantum PSA during canine and human visceral leishmaniasis,” Parasite Immunology, vol. 22, no. 2, pp. 55–62, 2000.
View at: Publisher Site | Google Scholar
E. Handman, F. M. Symons, T. M. Baldwin, J. M. Curtis, and J.-P. Y. Scheerlinck, “Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response,” Infection and Immunity, vol. 63, no. 11, pp. 4261–4267, 1995.
View at: Google Scholar
A. Sjölander, T. M. Baldwin, J. M. Curtis, and E. Handman, “Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to Leishmaniasis,” The Journal of Immunology, vol. 160, no. 8, pp. 3949–3957, 1998.
View at: Google Scholar
A. Sjölander, T. M. Baldwin, J. M. Curtis, K. L. Bengtsson, and E. Handman, “Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection,” Vaccine, vol. 16, no. 20, pp. 2077–2084, 1998.
View at: Publisher Site | Google Scholar
E. Handman, A. H. Noormohammadi, J. M. Curtis, T. Baldwin, and A. Sjölander, “Therapy of murine cutaneous leishmaniasis by DNA vaccination,” Vaccine, vol. 18, no. 26, pp. 3011–3017, 2000.
View at: Publisher Site | Google Scholar
E. Dumonteil, R.-S. Maria Jesus, E.-O. Javier, and G.-M. Maria del Rosario, “DNA vaccines induce partial protection against Leishmania mexicana,” Vaccine, vol. 21, no. 17-18, pp. 2161–2168, 2003.
View at: Publisher Site | Google Scholar
E. Dumonteil, F. Andrade-Narvarez, J. Escobedo-Ortegon et al., “Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana,” Developments in Biologicals, vol. 104, pp. 135–141, 2000.
View at: Google Scholar
D. McMahon-Pratt, D. Rodriguez, J.-R. Rodriguez et al., “Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection,” Infection and Immunity, vol. 61, no. 8, pp. 3351–3359, 1993.
View at: Google Scholar
D. L. Tolson, A. Jardim, L. F. Schnur et al., “The kinetoplastid membrane protein 11 of Leishmania donovani and African trypanosomes is a potent stimulator of T-lymphocyte proliferation,” Infection and Immunity, vol. 62, no. 11, pp. 4893–4899, 1994.
View at: Google Scholar
A. Jardim, V. Funk, R. M. Caprioli, and R. W. Olafson, “Isolation and structural characterization of the Leishmania donovani kinetoplastid membrane protein-11, a major immunoreactive membrane glycoprotein,” Biochemical Journal, vol. 305, part 1, pp. 307–313, 1995.
View at: Google Scholar
C. Berberich, J. M. Requena, and C. Alonso, “Cloning of genes and expression and antigenicity analysis of the Leishmania infantum KMP-11 protein,” Experimental Parasitology, vol. 85, no. 1, pp. 105–108, 1997.
View at: Publisher Site | Google Scholar
J. R. Ramírez, C. Berberich, A. Jaramillo, C. Alonso, and I. D. Vélez, “Molecular and antigenic characterization of the Leishmania (Viannia) panamensis kinetoplastid membrane protein-11,” Memórias do Instituto Oswaldo Cruz, vol. 93, no. 2, pp. 247–254, 1998.
View at: Google Scholar
A. T. R. Jensen, S. Gasim, A. Ismail et al., “Humoral and cellular immune responses to synthetic peptides of the Leishmania donovani kinetoplastid membrane protein-11,” Scandinavian Journal of Immunology, vol. 48, no. 1, pp. 103–109, 1998.
View at: Publisher Site | Google Scholar
C. Trujillo, R. Ramírez, I. D. Vélez, and C. Berberich, “The humoral immune response to the kinetoplastid membrane protein-11 in patients with American Leishmaniasis and Chagas disease: prevalence of IgG subclasses and mapping of epitopes,” Immunology Letters, vol. 70, no. 3, pp. 203–209, 2000.
View at: Publisher Site | Google Scholar
S. Passos, L. P. de Carvalho, G. Orge et al., “Recombinant Leishmania antigens for serodiagnosis of visceral leishmaniasis,” Clinical and Diagnostic Laboratory Immunology, vol. 12, no. 10, pp. 1164–1167, 2005.
View at: Publisher Site | Google Scholar
A. Jardim, D. L. Tolson, S. J. Turco, T. W. Pearson, and R. W. Olafson, “The Leishmania donovani lipophosphoglycan T lymphocyte-reactive component is a tightly associated protein complex,” The Journal of Immunology, vol. 147, no. 10, pp. 3538–3544, 1991.
View at: Google Scholar
E. Carrillo, M. Crusat, J. Nieto et al., “Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis,” Vaccine, vol. 26, no. 15, pp. 1902–1911, 2008.
View at: Publisher Site | Google Scholar
R. Basu, S. Bhaumik, J. M. Basu, K. Naskar, T. De, and S. Roy, “Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis,” The Journal of Immunology, vol. 174, no. 11, pp. 7160–7171, 2005.
View at: Google Scholar
J. R. Ramírez, K. Gilchrist, S. Robledo et al., “Attenuated Toxoplasma gondii ts-4 mutants engineered to express the Leishmania antigen KMP-11 elicit a specific immune response in BALB/c mice,” Vaccine, vol. 20, no. 3-4, pp. 455–461, 2001.
View at: Publisher Site | Google Scholar
P. G. McKean, R. Delahay, P. F. P. Pimenta, and D. F. Smith, “Characterisation of a second protein encoded by the differentially regulated LmcDNA16 gene family of Leishmania major,” Molecular and Biochemical Parasitology, vol. 85, no. 2, pp. 221–231, 1997.
View at: Publisher Site | Google Scholar
H. M. Flinn, D. Rangarajan, and D. F. Smith, “Expression of a hydrophilic surface protein in infective stages of Leishmania major,” Molecular and Biochemical Parasitology, vol. 65, no. 2, pp. 259–270, 1994.
View at: Publisher Site | Google Scholar
T. M. Alce, S. Gokool, D. McGhie, S. Stäger, and D. F. Smith, “Expression of hydrophilic surface proteins in infective stages of Leishmania donovani,” Molecular and Biochemical Parasitology, vol. 102, no. 1, pp. 191–196, 1999.
View at: Publisher Site | Google Scholar
A. T. R. Jensen, S. Gasim, T. Moller et al., “Serodiagnosis of Leishmania donovani infections: assessment of enzyme-linked immunosorbent assays using recombinant L. donovani gene B protein (GBP) and a peptide sequence of L. donovani GBP,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 93, no. 2, pp. 157–160, 1999.
View at: Publisher Site | Google Scholar
S. Stäger, D. F. Smith, and P. M. Kaye, “Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis,” The Journal of Immunology, vol. 165, no. 12, pp. 7064–7071, 2000.
View at: Google Scholar
J. Moreno, J. Nieto, S. Masina et al., “Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis,” Vaccine, vol. 25, no. 29, pp. 5290–5300, 2007.
View at: Publisher Site | Google Scholar
R. Badaró, D. Benson, M. C. Eulálio et al., “rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis,” The Journal of Infectious Diseases, vol. 173, no. 3, pp. 758–761, 1996.
View at: Google Scholar
K. G. J. Pollock, K. S. McNeil, J. C. Mottram et al., “The Leishmania mexicana cysteine protease, CPB2.8, induces potent Th2 responses,” The Journal of Immunology, vol. 170, no. 4, pp. 1746–1753, 2003.
View at: Google Scholar
S. Rafati, A. Nakhaee, T. Taheri et al., “Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis,” Experimental Parasitology, vol. 103, no. 3-4, pp. 143–151, 2003.
View at: Publisher Site | Google Scholar
E. Pateraki, R. Portocala, H. Labrousse, and J. L. Guesdon, “Antiactin and antitubulin antibodies in canine visceral leishmaniasis,” Infection and Immunity, vol. 42, no. 2, pp. 496–500, 1983.
View at: Google Scholar
K. Zemzoumi, E. Guilvard, D. Sereno et al., “Cloning of a Leishmania major gene encoding for an antigen with extensive homology to ribosomal protein S3a,” Gene, vol. 240, no. 1, pp. 57–65, 1999.
View at: Publisher Site | Google Scholar
Y. A. W. Skeiky, D. R. Benson, M. Elwasila, R. Badaro, J. M. Burns, Jr., and S. G. Reed, “Antigens shared by Leishmania species and Trypanosoma cruzi: immunological comparison of the acidic ribosomal P0 proteins,” Infection and Immunity, vol. 62, no. 5, pp. 1643–1651, 1994.
View at: Google Scholar
A. M. Montalvo-Álvarez, C. Folgueira, J. Carrión, L. Monzote-Fidalgo, C. Cañavate, and J. M. Requena, “The Leishmania HSP20 is antigenic during natural infections, but, as DNA vaccine, it does not protect BALB/c mice against experimental L. amazonensis infection,” Journal of Biomedicine and Biotechnology, vol. 2008, Article ID 695432, 9 pages, 2008.
View at: Publisher Site | Google Scholar
J. A. Rey-Ladino, P. B. Joshi, B. Singh, R. Gupta, and N. E. Reiner, “Leishmania major: molecular cloning, sequencing, and expression of the heat shock protein 60 gene reveals unique carboxy terminal peptide sequences,” Experimental Parasitology, vol. 85, no. 3, pp. 249–263, 1997.
View at: Publisher Site | Google Scholar
L. Quijada, J. M. Requena, M. Soto, and C. Alonso, “During canine viscero-cutaneous leishmaniasis the anti-Hsp70 antibodies are specifically elicited by the parasite protein,” Parasitology, vol. 112, part 3, pp. 277–284, 1996.
View at: Google Scholar
R. Larreta, M. Soto, C. Alonso, and J. M. Requena, “Leishmania infantum: gene cloning of the GRP94 homologue, its expression as recombinant protein, and analysis of antigenicity,” Experimental Parasitology, vol. 96, no. 2, pp. 108–115, 2000.
View at: Publisher Site | Google Scholar
M. Soto, J. M. Requena, L. Quijada et al., “Antigenicity of the Leishmania infantum histones H2B and H4 during canine viscerocutaneous leishmaniasis,” Clinical & Experimental Immunology, vol. 115, no. 2, pp. 342–349, 1999.
View at: Publisher Site | Google Scholar
S. Rafati, A.-H. Salmanian, K. Hashemi, C. Schaff, S. Belli, and N. Fasel, “Identification of Leishmania major cysteine proteinases as targets of the immune response in humans,” Molecular and Biochemical Parasitology, vol. 113, no. 1, pp. 35–43, 2001.
View at: Publisher Site | Google Scholar
N. Khoshgoo, F. Zahedifard, H. Azizi, Y. Taslimi, M. J. Alonso, and S. Rafati, “Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals,” Vaccine, vol. 26, no. 46, pp. 5822–5829, 2008.
View at: Publisher Site | Google Scholar
J. M. Burns, Jr., W. G. Shreffler, D. R. Benson, H. W. Ghalib, R. Badaro, and S. G. Reed, “Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 2, pp. 775–779, 1993.
View at: Publisher Site | Google Scholar
M. T. M. Roberts, C. B. Stober, A. N. McKenzie, and J. M. Blackwell, “Interleukin-4 (IL-4) and IL-10 collude in vaccine failure for novel exacerbatory antigens in murine Leishmania major infection,” Infection and Immunity, vol. 73, no. 11, pp. 7620–7628, 2005.
View at: Publisher Site | Google Scholar
A. Cordeiro-da-Silva, M. C. Borges, E. Guilvard, and A. Ouaissi, “Dual role of the Leishmania major ribosomal protein S3a homologue in regulation of T- and B-cell activation,” Infection and Immunity, vol. 69, no. 11, pp. 6588–6596, 2001.
View at: Publisher Site | Google Scholar
M. Soto, J. M. Requena, L. Quijada, F. Guzman, M. E. Patarroyo, and C. Alonso, “Identification of the Leishmania infantum P0 ribosomal protein epitope in canine visceral leishmaniasis,” Immunology Letters, vol. 48, no. 1, pp. 23–28, 1995.
View at: Publisher Site | Google Scholar
M. Soto, J. M. Requena, L. Quijada et al., “During active viscerocutaneous leishmaniasis the anti-P2 humoral response is specifically triggered by the parasite P proteins,” Clinical & Experimental Immunology, vol. 100, no. 2, pp. 246–252, 1995.
View at: Google Scholar
M. J. Levin, M. Vazquez, D. Kaplan, and A. G. Schijman, “The Trypanosoma cruzi ribosomal P protein family: classification and antigenicity,” Parasitology Today, vol. 9, no. 10, pp. 381–384, 1993.
View at: Publisher Site | Google Scholar
S. Iborra, D. R. Abánades, N. Parody et al., “The immunodominant T helper 2 (Th2) response elicited in BALB/c mice by the Leishmania LiP2a and LiP2b acidic ribosomal proteins cannot be reverted by strong Th1 inducers,” Clinical & Experimental Immunology, vol. 150, no. 2, pp. 375–385, 2007.
View at: Google Scholar
M. Soto, C. Alonso, and J. M. Requena, “The Leishmania infantum acidic ribosomal protein LiP2a induces a prominent humoral response in vivo and stimulates cell proliferation in vitro and interferon-gamma (IFN- $γ$ ) production by murine splenocytes,” Clinical & Experimental Immunology, vol. 122, no. 2, pp. 212–218, 2000.
View at: Publisher Site | Google Scholar
M. Soto, J. M. Requena, L. Quijada, and C. Alonso, “Specific serodiagnosis of human leishmaniasis with recombinant Leishmania P2 acidic ribosomal proteins,” Clinical and Diagnostic Laboratory Immunology, vol. 3, no. 4, pp. 387–391, 1996.
View at: Google Scholar
K. Elkon, S. Skelly, A. Parnassa et al., “Identification and chemical synthesis of a ribosomal protein antigenic determinant in systemic lupus erythematosus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 19, pp. 7419–7423, 1986.
View at: Google Scholar
C. Mayer, U. Appenzeller, H. Seelbach et al., “Humoral and cell-mediated autoimmune reactions to human acidic ribosomal $P_{2}$ protein in individuals sensitized to Aspergillus fumigatus $P_{2}$ protein,” Journal of Experimental Medicine, vol. 189, no. 9, pp. 1507–1512, 1999.
View at: Publisher Site | Google Scholar
Y. A. W. Skeiky, D. R. Benson, M. Parsons, K. B. Elkon, and S. G. Reed, “Cloning and expression of Trypanosoma cruzi ribosomal protein P0 and epitope analysis of anti-P0 autoantibodies in Chagas' disease patients,” Journal of Experimental Medicine, vol. 176, no. 1, pp. 201–211, 1992.
View at: Publisher Site | Google Scholar
S. Iborra, M. Soto, J. Carrión et al., “The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice,” Infection and Immunity, vol. 71, no. 11, pp. 6562–6572, 2003.
View at: Publisher Site | Google Scholar
S. Iborra, J. Carrión, C. Anderson, C. Alonso, D. Sacks, and M. Soto, “Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice,” Infection and Immunity, vol. 73, no. 9, pp. 5842–5852, 2005.
View at: Publisher Site | Google Scholar
E. Arndt and C. Weigel, “Nucleotide sequence of the genes encoding the L11, L1, L10 and L12 equivalent ribosomal proteins from the archaebacterium Halobacterium marismortui,” Nucleic Acids Research, vol. 18, no. 5, p. 1285, 1990.
View at: Google Scholar
D. B. Young, “Heat-shock proteins: immunity and autoimmunity,” Current Opinion in Immunology, vol. 4, no. 4, pp. 396–400, 1992.
View at: Google Scholar
C. Folgueira and J. M. Requena, “A postgenomic view of the heat shock proteins in kinetoplastids,” FEMS Microbiology Reviews, vol. 31, no. 4, pp. 359–377, 2007.
View at: Publisher Site | Google Scholar
B. J. Celeste, S. O. Angel, L. G. M. Castro, M. Gidlund, and H. Goto, “Leishmania infantum heat shock protein 83 for the serodiagnosis of tegumentary leishmaniasis,” Brazilian Journal of Medical and Biological Research, vol. 37, no. 11, pp. 1591–1593, 2004.
View at: Google Scholar
S. K. Gupta, B. S. Sisodia, S. Sinha et al., “Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes,” Proteomics, vol. 7, no. 5, pp. 816–823, 2007.
View at: Publisher Site | Google Scholar
A. Descoteaux, H. A. Avila, K. Zhang, S. J. Turco, and S. M. Beverley, “Leishmania LPG3 encodes a GRP94 homolog required for phosphoglycan synthesis implicated in parasite virulence but not viability,” The EMBO Journal, vol. 21, no. 17, pp. 4458–4469, 2002.
View at: Publisher Site | Google Scholar
R. Larreta, F. Guzman, M. E. Patarroyo, C. Alonso, and J. M. Requena, “Antigenic properties of the Leishmania infantum GRP94 and mapping of linear B-cell epitopes,” Immunology Letters, vol. 80, no. 3, pp. 199–205, 2002.
View at: Publisher Site | Google Scholar
L. Quijada, J. M. Requena, M. Soto, and C. Alonso, “Analysis of the antigenic properties of the L. infantum Hsp70: design of synthetic peptides for specific serodiagnosis of human leishmaniasis,” Immunology Letters, vol. 63, no. 3, pp. 169–174, 1998.
View at: Publisher Site | Google Scholar
A. I. Zurita, J. Rodríguez, J. E. Piñero et al., “Cloning and characterization of the Leishmania (Viannia) braziliensis HSP70 gene. Diagnostic use of the C-terminal fragment rlb70(513–663),” Journal of Parasitology, vol. 89, no. 2, pp. 372–378, 2003.
View at: Publisher Site | Google Scholar
P. Echeverria, G. Dran, G. Pereda et al., “Analysis of the adjuvant effect of recombinant Leishmania infantum Hsp83 protein as a tool for vaccination,” Immunology Letters, vol. 76, no. 2, pp. 107–110, 2001.
View at: Publisher Site | Google Scholar
A. I. Rico, G. Del Real, M. Soto et al., “Characterization of the immunostimulatory properties of Leishmania infantum HSP70 by fusion to the Escherichia coli maltose-binding protein in normal and nu/nu BALB/c mice,” Infection and Immunity, vol. 66, no. 1, pp. 347–352, 1998.
View at: Google Scholar
S. Rafati, E. Gholami, N. Hassani et al., “Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients,” Vaccine, vol. 25, no. 21, pp. 4159–4169, 2007.
View at: Publisher Site | Google Scholar
J. R. Webb, A. Campos-Neto, Y. A. W. Skeiky, and S. G. Reed, “Molecular characterization of the heat-inducible LmSTI1 protein of Leishmania major,” Molecular and Biochemical Parasitology, vol. 89, no. 2, pp. 179–193, 1997.
View at: Publisher Site | Google Scholar
A. Campos-Neto, R. Porrozzi, K. Greeson et al., “Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease,” Infection and Immunity, vol. 69, no. 6, pp. 4103–4108, 2001.
View at: Publisher Site | Google Scholar
A. Campos-Neto, J. R. Webb, K. Greeson, R. N. Coler, Y. A. W. Skeiky, and S. G. Reed, “Vaccination with plasmid DNA encoding TSA/LmSTI1 Leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice,” Infection and Immunity, vol. 70, no. 6, pp. 2828–2836, 2002.
View at: Publisher Site | Google Scholar
A. Badiee, M. R. Jaafari, A. Samiei, D. Soroush, and A. Khamesipour, “Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice,” Clinical and Vaccine Immunology, vol. 15, no. 4, pp. 668–674, 2008.
View at: Publisher Site | Google Scholar
M. Soto, J. M. Requena, L. Quijada et al., “Mapping of the linear antigenic determinants from the Leishmania infantum histone H2A recognized by sera from dogs with leishmaniasis,” Immunology Letters, vol. 48, no. 3, pp. 209–214, 1995.
View at: Publisher Site | Google Scholar
M. Soto, J. M. Requena, L. Quijada et al., “Characterization of the antigenic determinants of the Leishmania infantum histone H3 recognized by antibodies elicited during canine visceral leishmaniasis,” Clinical & Experimental Immunology, vol. 106, no. 3, pp. 454–461, 1996.
View at: Publisher Site | Google Scholar
Y. Montoya, C. Leon, M. Talledo et al., “Recombinant antigens for specific and sensitive serodiagnosis of Latin American tegumentary leishmaniasis,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 91, no. 6, pp. 674–676, 1997.
View at: Publisher Site | Google Scholar
L. P. de Carvalho, M. Soto, S. Jerônimo et al., “Characterization of the immune response to Leishmania infantum recombinant antigens,” Microbes and Infection, vol. 5, no. 1, pp. 7–12, 2003.
View at: Publisher Site | Google Scholar
S. Iborra, M. Soto, J. Carrión, C. Alonso, and J. M. Requena, “Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis,” Vaccine, vol. 22, no. 29-30, pp. 3865–3876, 2004.
View at: Publisher Site | Google Scholar
J. Carrión, A. Nieto, M. Soto, and C. Alonso, “Adoptive transfer of dendritic cells pulsed with Leishmania infantum nucleosomal histones confers protection against cutaneous leishmaniosis in BALB/c mice,” Microbes and Infection, vol. 9, no. 6, pp. 735–743, 2007.
View at: Publisher Site | Google Scholar
J. Carrión, C. Folgueira, and C. Alonso, “Transitory or long-lasting immunity to Leishmania major infection: the result of immunogenicity and multicomponent properties of histone DNA vaccines,” Vaccine, vol. 26, no. 9, pp. 1155–1165, 2008.
View at: Publisher Site | Google Scholar
J. Carrión, C. Folgueira, and C. Alonso, “Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells,” Vaccine, vol. 26, no. 20, pp. 2537–2544, 2008.
View at: Publisher Site | Google Scholar
M. Chenik, H. Louzir, H. Ksontini, A. Dilou, I. Abdmouleh, and K. Dellagi, “Vaccination with the divergent portion of the protein histone H2B of Leishmania protects susceptible BALB/c mice against a virulent challenge with Leishmania major,” Vaccine, vol. 24, no. 14, pp. 2521–2529, 2006.
View at: Publisher Site | Google Scholar
D. Smirlis, S. N. Bisti, E. Xingi, G. Konidou, M. Thiakaki, and K. P. Soteriadou, “Leishmania histone H1 overexpression delays parasite cell-cycle progression, parasite differentiation and reduces Leishmania infectivity in vivo,” Molecular Microbiology, vol. 60, no. 6, pp. 1457–1473, 2006.
View at: Publisher Site | Google Scholar
F. T. Papageorgiou and K. P. Soteriadou, “Expression of a novel Leishmania gene encoding a histone H1-like protein in Leishmania major modulates parasite infectivity in vitro,” Infection and Immunity, vol. 70, no. 12, pp. 6976–6986, 2002.
View at: Publisher Site | Google Scholar
N. Solioz, U. Blum-Tirouvanziam, R. Jacquet et al., “The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis,” Vaccine, vol. 18, no. 9-10, pp. 850–859, 1999.
View at: Publisher Site | Google Scholar
S. Masina, M. M. Gicheru, S. O. Demotz, and N. J. Fasel, “Protection against cutaneous leishmaniasis in outbred vervet monkeys using a recombinant histone H1 antigen,” The Journal of Infectious Diseases, vol. 188, no. 8, pp. 1250–1257, 2003.
View at: Publisher Site | Google Scholar
J. H. McKerrow, E. Sun, P. J. Rosenthal, and J. Bouvier, “The proteases and pathogenicity of parasitic protozoa,” Annual Review of Microbiology, vol. 47, pp. 821–853, 1993.
View at: Publisher Site | Google Scholar
J. A. Sakanari, S. A. Nadler, V. J. Chan, J. C. Engel, C. Leptak, and J. Bouvier, “Leishmania major: comparison of the cathepsin L- and B-like cysteine protease genes with those of other trypanosomatids,” Experimental Parasitology, vol. 85, no. 1, pp. 63–76, 1997.
View at: Publisher Site | Google Scholar
J. C. Mottram, D. R. Brooks, and G. H. Coombs, “Roles of cysteine proteinases of trypanosomes and Leishmania in host-parasite interactions,” Current Opinion in Microbiology, vol. 1, no. 4, pp. 455–460, 1998.
View at: Publisher Site | Google Scholar
J. C. Mottram, A. E. Souza, J. E. Hutchison, R. Carter, M. J. Frame, and G. H. Coombs, “Evidence from disruption of the lmcpb gene array of Leishmania mexicana that cysteine proteinases are virulence factors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 12, pp. 6008–6013, 1996.
View at: Publisher Site | Google Scholar
L. U. Buxbaum, H. Denise, G. H. Coombs, J. Alexander, J. C. Mottram, and P. Scott, “Cysteine protease B of Leishmania mexicana inhibits host Th1 responses and protective immunity,” The Journal of Immunology, vol. 171, no. 7, pp. 3711–3717, 2003.
View at: Google Scholar
J. Alexander and K. Bryson, “T helper (h)1/Th2 and Leishmania: paradox rather than paradigm,” Immunology Letters, vol. 99, no. 1, pp. 17–23, 2005.
View at: Publisher Site | Google Scholar
S. de Souza Dias, P. H. da Costa Pinheiro, S. Katz, M. R. Machado dos Santos, and C. L. Barbiéri, “A recombinant cysteine proteinase from Leishmania (Leishmania) chagasi suitable for serodiagnosis of American visceral leishmaniasis,” The American Journal of Tropical Medicine and Hygiene, vol. 72, no. 2, pp. 126–132, 2005.
View at: Google Scholar
H. Pascalis, A. Lavergne, E. Bourreau et al., “Th1 cell development induced by cysteine proteinases A and B in localized cutaneous leishmaniasis due to Leishmania guyanensis,” Infection and Immunity, vol. 71, no. 5, pp. 2924–2926, 2003.
View at: Publisher Site | Google Scholar
A. Zadeh-Vakili, T. Taheri, Y. Taslimi, F. Doustdari, A.-H. Salmanian, and S. Rafati, “Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis,” Vaccine, vol. 22, no. 15-16, pp. 1930–1940, 2004.
View at: Publisher Site | Google Scholar
P. H. da Costa Pinheiro, S. de Souza Dias, K. Dantas Eulálio, I. L. Mendonça, S. Katz, and C. L. Barbiéri, “Recombinant cysteine proteinase from Leishmania (Leishmania) chagasi implicated in human and dog T-cell responses,” Infection and Immunity, vol. 73, no. 6, pp. 3787–3789, 2005.
View at: Publisher Site | Google Scholar
S. Rafati, A.-H. Salmanian, T. Taheri, M. Vafa, and N. Fasel, “A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major,” Vaccine, vol. 19, no. 25-26, pp. 3369–3375, 2001.
View at: Publisher Site | Google Scholar
S. Rafati, A. Kariminia, S. Seyde-Eslami, M. Narimani, T. Taheri, and M. Lebbatard, “Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing ${CD8}^{+}$ T lymphocyte activation,” Vaccine, vol. 20, no. 19-20, pp. 2439–2447, 2002.
View at: Publisher Site | Google Scholar
S. Rafati, F. Zahedifard, and F. Nazgouee, “Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis,” Vaccine, vol. 24, no. 12, pp. 2169–2175, 2006.
View at: Publisher Site | Google Scholar
S. Rafati, A. Nakhaee, T. Taheri et al., “Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum,” Vaccine, vol. 23, no. 28, pp. 3716–3725, 2005.
View at: Publisher Site | Google Scholar
J. Poot, K. Spreeuwenberg, S. J. Sanderson et al., “Vaccination with a preparation based on recombinant cysteine peptidases and canine IL-12 does not protect dogs from infection with Leishmania infantum,” Vaccine, vol. 24, no. 14, pp. 2460–2468, 2006.
View at: Publisher Site | Google Scholar
P. Probst, Y. A. W. Skeiky, M. Steeves, A. Gervassi, K. H. Grabstein, and S. G. Reed, “A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor- $α$ production and expression of B7-1 in human monocyte-derived antigen-presenting cells,” European Journal of Immunology, vol. 27, no. 10, pp. 2634–2642, 1997.
View at: Publisher Site | Google Scholar
Y. A. W. Skeiky, M. Kennedy, D. Kaufman et al., “LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile,” The Journal of Immunology, vol. 161, no. 11, pp. 6171–6179, 1998.
View at: Google Scholar
M. M. Borges, A. Campos-Neto, P. Sleath et al., “Potent stimulation of the innate immune system by a Leishmania brasiliensis recombinant protein,” Infection and Immunity, vol. 69, no. 9, pp. 5270–5277, 2001.
View at: Publisher Site | Google Scholar
P. Launois, I. Maillard, S. Pingel et al., “IL-4 rapidly produced by V $β$ 4 V $α$ 8 ${CD4}^{+}$ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice,” Immunity, vol. 6, no. 5, pp. 541–549, 1997.
View at: Publisher Site | Google Scholar
S. Gurunathan, D. L. Sacks, D. R. Brown et al., “Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major,” Journal of Experimental Medicine, vol. 186, no. 7, pp. 1137–1147, 1997.
View at: Publisher Site | Google Scholar
V. Julia, M. Rassoulzadegan, and N. Glaichenhaus, “Resistance to Leishmania major induced by tolerance to a single antigen,” Science, vol. 274, no. 5286, pp. 421–423, 1996.
View at: Publisher Site | Google Scholar
S. Ben Hadj Ahmed, C. Bahloul, C. Robbana, S. Askri, and K. Dellagi, “A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major,” Vaccine, vol. 22, no. 13-14, pp. 1631–1639, 2004.
View at: Publisher Site | Google Scholar
N. Soussi, H. Saklani-Jusforgues, J.-H. Colle, G. Milon, N. Glaichenhaus, and P. L. Goossens, “Effect of intragastric and intraperitoneal immunisation with attenuated and wild-type LACK-expressing Listeria monocytogenes on control of murine Leishmania major infection,” Vaccine, vol. 20, no. 21-22, pp. 2702–2712, 2002.
View at: Publisher Site | Google Scholar
R. M. Gonzalo, J. R. Rodríguez, D. Rodríguez, G. González-Aseguinolaza, V. Larraga, and M. Esteban, “Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36,” Microbes and Infection, vol. 3, no. 9, pp. 701–711, 2001.
View at: Publisher Site | Google Scholar
R. M. Gonzalo, G. del Real, J. R. Rodriguez et al., “A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis,” Vaccine, vol. 20, no. 7-8, pp. 1226–1231, 2002.
View at: Publisher Site | Google Scholar
E. Pérez-Jiménez, G. Kochan, M. M. Gherardi, and M. Esteban, “MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis,” Microbes and Infection, vol. 8, no. 3, pp. 810–822, 2006.
View at: Publisher Site | Google Scholar
E. A .F. Coelho, C. A. P. Tavares, F. A. A. Carvalho et al., “Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection,” Infection and Immunity, vol. 71, no. 7, pp. 3988–3994, 2003.
View at: Publisher Site | Google Scholar
T. Okuno, M. Takeuchi, Y. Matsumoto, H. Otsuka, and Y. Matsumoto, “Pretreatment of Leishmania homologue of receptors for activated C kinase (LACK) promotes disease progression caused by Leishmania amazonensis,” Experimental Animals, vol. 51, no. 4, pp. 335–341, 2002.
View at: Publisher Site | Google Scholar
E. F. Pinto, R. O. Pinheiro, A. Rayol, V. Larraga, and B. Rossi-Bergmann, “Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK,” Infection and Immunity, vol. 72, no. 8, pp. 4521–4527, 2004.
View at: Publisher Site | Google Scholar
P. C. Melby, J. Yang, W. Zhao, L. E. Perez, and J. Cheng, “Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis,” Infection and Immunity, vol. 69, no. 8, pp. 4719–4725, 2001.
View at: Publisher Site | Google Scholar
E. A. Marques-da-Silva, E. A .F. Coelho, D. C. O. Gomes et al., “Intramuscular immunization with p36(LACK) DNA vaccine induces IFN- $γ$ production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge,” Parasitology Research, vol. 98, no. 1, pp. 67–74, 2005.
View at: Publisher Site | Google Scholar
M. J. Ramiro, J. J. Zárate, T. Hanke et al., “Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK,” Vaccine, vol. 21, no. 19-20, pp. 2474–2484, 2003.
View at: Publisher Site | Google Scholar
I. Ramos, A. Alonso, J. M. Marcen et al., “Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response,” Vaccine, vol. 26, no. 3, pp. 333–344, 2008.
View at: Publisher Site | Google Scholar
B. Dondji, E. Pérez-Jimenez, K. Goldsmith-Pestana, M. Esteban, and D. McMahon-Pratt, “Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis,” Infection and Immunity, vol. 73, no. 8, pp. 5286–5289, 2005.
View at: Publisher Site | Google Scholar
W.-W. Zhang, H. Charest, E. Ghedin, and G. Matlashewski, “Identification and overexpression of the A2 amastigote-specific protein in Leishmania donovani,” Molecular and Biochemical Parasitology, vol. 78, no. 1-2, pp. 79–90, 1996.
View at: Publisher Site | Google Scholar
D. R. A. Martins, S. M. B. Jeronimo, J. E. Donelson, and M. E. Wilson, “Leishmania chagasi T-cell antigens identified through a double library screen,” Infection and Immunity, vol. 74, no. 12, pp. 6940–6948, 2006.
View at: Publisher Site | Google Scholar
E. Ghedin, W. W. Zhang, H. Charest, S. Sundar, R. T. Kenney, and G. Matlashewski, “Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis,” Clinical and Diagnostic Laboratory Immunology, vol. 4, no. 5, pp. 530–535, 1997.
View at: Google Scholar
F. A. A. Carvalho, H. Charest, C. A. P. Tavares et al., “Diagnosis of American visceral leishmaniasis in humans and dogs using the recombinant Leishmania donovani A2 antigen,” Diagnostic Microbiology and Infectious Disease, vol. 43, no. 4, pp. 289–295, 2002.
View at: Publisher Site | Google Scholar
A. Ghosh, S. Labrecque, and G. Matlashewski, “Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response,” Vaccine, vol. 19, no. 23-24, pp. 3169–3178, 2001.
View at: Publisher Site | Google Scholar
A. Ghosh, W. W. Zhang, and G. Matlashewski, “Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections,” Vaccine, vol. 20, no. 1-2, pp. 59–66, 2001.
View at: Publisher Site | Google Scholar
A. P. Fernandes, M. M. S. Costa, E. A. F. Coelho et al., “Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein,” Vaccine, vol. 26, no. 46, pp. 5888–5895, 2008.
View at: Publisher Site | Google Scholar
S. F. Guimarães Carvalho, E. M. Lemos, R. Corey, and R. Dietze, “Performance of recombinant K39 antigen in the diagnosis of Brazilian visceral leishmaniasis,” The American Journal of Tropical Medicine and Hygiene, vol. 68, no. 3, pp. 321–324, 2003.
View at: Google Scholar
F. J. Medrano, C. Cañavate, M. Leal, C. Rey, E. Lissen, and J. Alvar, “The role of serology in the diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type- 1,” The American Journal of Tropical Medicine and Hygiene, vol. 59, no. 1, pp. 155–162, 1998.
View at: Google Scholar
S. Singh, V. Kumari, and N. Singh, “Predicting kala-azar disease manifestations in asymptomatic patients with latent Leishmania donovani infection by detection of antibody against recombinant K39 antigen,” Clinical and Diagnostic Laboratory Immunology, vol. 9, no. 3, pp. 568–572, 2002.
View at: Publisher Site | Google Scholar
H. Veeken, K. Ritmeijer, J. Seaman, and R. Davidson, “Comparison of an rK39 dipstick rapid test with direct agglutination test and splenic aspiration for the diagnosis of kala-azar in Sudan,” Tropical Medicine & International Health, vol. 8, no. 2, pp. 164–167, 2003.
View at: Publisher Site | Google Scholar
E. E. Zijlstra, Y. Nur, P. Desjeux, E. A. G. Khalil, A. M. El-Hassan, and J. Groen, “Diagnosing visceral leishmaniasis with the recombinant K39 strip test: experience from the Sudan,” Tropical Medicine & International Health, vol. 6, no. 2, pp. 108–113, 2001.
View at: Publisher Site | Google Scholar
R. Porrozzi, M. V. Santos da Costa, A. Teva et al., “Comparative evaluation of enzyme-linked immunosorbent assays based on crude and recombinant leishmanial antigens for serodiagnosis of symptomatic and asymptomatic Leishmania infantum visceral infections in dogs,” Clinical and Vaccine Immunology, vol. 14, no. 5, pp. 544–548, 2007.
View at: Publisher Site | Google Scholar
S. O. Toz, K.-P. Chang, Y. Ozbel, and M. Z. Alkan, “Diagnostic value of RK39 dipstick in zoonotic visceral leishmaniasis in Turkey,” Journal of Parasitology, vol. 90, no. 6, pp. 1484–1486, 2004.
View at: Publisher Site | Google Scholar
R. T. da Costa, J. C. França, W. Mayrink, E. Nascimento, O. Genaro, and A. Campos-Neto, “Standardization of a rapid immunochromatographic test with the recombinant antigens K39 and K26 for the diagnosis of canine visceral leishmaniasis,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 97, no. 6, pp. 678–682, 2003.
View at: Publisher Site | Google Scholar
D. Otranto, P. Paradies, M. Sasanelli et al., “Recombinant K39 dipstick immunochromatographic test: a new tool for the serodiagnosis of canine leishmaniasis,” Journal of Veterinary Diagnostic Investigation, vol. 17, no. 1, pp. 32–37, 2005.
View at: Google Scholar
A. Dey, P. Sharma, N. S. Redhu, and S. Singh, “Kinesin motor domain of Leishmania donovani as a future vaccine candidate,” Clinical and Vaccine Immunology, vol. 15, no. 5, pp. 836–842, 2008.
View at: Publisher Site | Google Scholar
Y. Belkaid, S. Mendez, R. Lira, N. Kadambi, G. Milon, and D. Sacks, “A natural model of Leishmania major infection reveals a prolonged “silent” phase of parasite amplification in the skin before the onset of lesion formation and immunity,” The Journal of Immunology, vol. 165, no. 2, pp. 969–977, 2000.
View at: Google Scholar
S. Méndez, S. Gurunathan, S. Kamhawi et al., “The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge,” The Journal of Immunology, vol. 166, no. 8, pp. 5122–5128, 2001.
View at: Google Scholar
R. T. Fujiwara, A. M. Vale, J. C. França da Silva et al., “Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis,” Veterinary Research, vol. 36, no. 5-6, pp. 827–838, 2005.
View at: Publisher Site | Google Scholar
Y. A. W. Skeiky, R. N. Coler, M. Brannon et al., “Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL $^{®}$ adjuvant,” Vaccine, vol. 20, no. 27-28, pp. 3292–3303, 2002.
View at: Publisher Site | Google Scholar
R. N. Coler, Y. A. W. Skeiky, K. Bernards et al., “Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis,” Infection and Immunity, vol. 70, no. 8, pp. 4215–4225, 2002.
View at: Publisher Site | Google Scholar
R. N. Coler, Y. Goto, L. Bogatzki, V. Raman, and S. G. Reed, “Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of ${CD4}^{+}$ T cells,” Infection and Immunity, vol. 75, no. 9, pp. 4648–4654, 2007.
View at: Publisher Site | Google Scholar
A. Boarino, A. Scalone, L. Gradoni et al., “Development of recombinant chimeric antigen expressing immunodominant B epitopes of Leishmania infantum for serodiagnosis of visceral leishmaniasis,” Clinical and Diagnostic Laboratory Immunology, vol. 12, no. 5, pp. 647–653, 2005.
View at: Publisher Site | Google Scholar
M. Soto, J. M. Requena, L. Quijada, and C. Alonso, “Multicomponent chimeric antigen for serodiagnosis of canine visceral leishmaniasis,” Journal of Clinical Microbiology, vol. 36, no. 1, pp. 58–63, 1998.
View at: Google Scholar
N. Parody, M. Soto, J. M. Requena, and C. Alonso, “Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG + Q mix protects Balb/c mice from infection,” Parasite Immunology, vol. 26, no. 6-7, pp. 283–293, 2004.
View at: Publisher Site | Google Scholar
I. Molano, M. García Alonso, C. Mirón et al., “A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum,” Veterinary Immunology and Immunopathology, vol. 92, no. 1-2, pp. 1–13, 2003.
View at: Publisher Site | Google Scholar
K.-P. Chang and B. S. McGwire, “Molecular determinants and regulation of Leishmania virulence,” Kinetoplastid Biology and Disease, vol. 1, article 1, pp. 1–7, 2002.
View at: Publisher Site | Google Scholar
K.-P. Chang, S. G. Reed, B. S. McGwire, and L. Soong, “Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity,” Acta Tropica, vol. 85, no. 3, pp. 375–390, 2003.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2009 Manuel Soto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

1116

Downloads

0

Citations